Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.49 |
| ▸ | APP | P05067 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447848 | 0.88 | BACE1 (0.59) | BACE1APPCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL449162 | 0.88 | BACE1 (0.46) | BACE1APPCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2557900 | 0.85 | BACE1 (0.36) | BACE1APPCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL446897 | 0.85 | BACE1 (0.43) | BACE1APPCTSD | |
| SCHEMBL448287 | 0.82 | BACE1 (0.49) | BACE1APPCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL446300 | 0.79 | BACE1 (0.58) | BACE1BACE2CTSD | |
| SCHEMBL445211 | 0.78 | BACE1 (0.73) | BACE1BACE2CTSD | |
| SCHEMBL447947 | 0.78 | BACE1 (0.61) | BACE1APPBACE2CTSD | |
| SCHEMBL448135 | 0.78 | BACE1 (0.47) | BACE1CYP2C9CTSD | |
| SCHEMBL2561886 | 0.75 | BACE1 (0.36) | BACE1APPCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885APP 1/4885CYP3A4 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.